Nectar Lifesciences Ltd, an integrated pharmaceutical organisation, offering a comprehensive range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), has plans to foray into regulated markets like European Union, USA, Europe and Japan for Cephalosporin Formulations. The company has plans to file 56 ANDA (Abbreviated New Drug Application) and dossiers in next 4-5 years to tap the regulated markets. The filing of ANDAs by the company in different regulated markets is likely to attract an investment of Rs 300 crore.
The company has state-of-the-art manufacturing facility in Baddi (Himachal Pradesh) to produce formulations, spread over 10 acres. The company has a per annum installed capacity to produce 1950 million tablets and capsules, 174 million injections, and 258 million bottles of oral suspensions. Currently, the company is utilising 25-30 per cent of its installed capacity. Besides catering to the domestic market, it is exporting to Asian and CIS countries.
Besides formulation, the company has also laid key emphasis on value added third and fourth generation APIs. The company has a manufacturing facility at Derabassi (Punjab) for the manufacturing of oral and sterile range of APIs and formulations, which is spread over 60 acres of land.
In the last financial year, the company had a turnover of Rs 1116 crore and this year it is hopeful to touch Rs 1400 crore. Recently, NecLife had launched 300 brands of generic drugs and it is expecting Rs 50 crore from the generic business this year. Besides that the company has also forayed into high end diagnostics and setting up their own unit in Derabassi (Punjab).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |